The figures, for anyone assembling their own picture. Practical: unopened, refrigerated at 2 to 8°C; in use, refrigerated and used within the preservative-limited window; never frozen; and a visual check every time — a haze that does not settle is a reason to stop, not to wonder.
One thing that is still open after chris_chi24’s answer:
What a temperature excursion actually does, and what distinguishes an unopened vial from one already in use?
Dr.PulmRoch said:Practical: unopened, refrigerated at 2 to 8°C; in use, refrigerated and used within the preservative-limited window; never frozen; and a visual check…
Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:
- Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
- Arg34 substitution: improved chemical stability
- C18 fatty diacid at Lys26: albumin binding → long half-life
These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsReporting back.
Closing this out: the trough rather than the peak explains the pattern I was seeing on day six, which I had been blaming on the vial.
Dr.LipidDallas said:Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).
PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:
- Tmax: 24-72 hours post-injection
- T½: ~168 hours (7 days) — enables weekly dosing
- Steady state: reached at 4-5 weeks
- Bioavailability (SubQ): ~89%
- Volume of distribution: ~12.5L (primarily plasma)
The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.